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Assessment of Myocardial Perfusion by Positron 
Emission Tomography 
Markus Schwaiger, MD and Otto Muzik, PhD 
Positron emission tomography (PET) represents 
an advanced Imaging technology for the noninva. 
sire evaluation of regional myocardial blood flow. 
Several blood flow tracers are available, includ- 
ing cyclotron.produced radiopharmaceuticals 
such as ["O]H20 and [UN]NHs and generator.pro. 
duced rubidium-82 ([~Rb].) and copper.62 ([~Cu]-) 
pyruvaldehyde-bis-(N-4-methylthiosemicarba. 
zone) (PTSM). nRb and ["N]NH 3 are the most com. 
monly employed tracers for the qualitative evalu- 
ation of regional myocardial perfusion. Their use 
allows the accurate detection of coronary artery 
disease In combination with pharmacologic 
stress. Initial comparative studies with thallium. 
201 (:°~TI) single-photon emission computed to- 
mography (SPECT) have shown that PET has a 
higher diagnostic accuracy. 
Beyond improved diagnostic performance, the 
quantitative flow measurements provided by PET 
represent an important advance in nuclear cardi. 
oiogy. The radiophermaceatica!s ['"O]H20 and 
[~'N]NH a have -It~n applied for the noninvasive 
determination of regional coronary reserve. 
Quantification of blood flow based on tracer ki- 
netic modeling yields blood flow values in close 
agr==.-mmt with determinations provided by inva- 
sive procedures, llhe nonlnvasive quantification 
of blood flow provides a useful research and clini- 
cal tool for the objective assessment of thera- 
peatic interventions as well as pathephysiologic 
alterations of regional myocardial blood flow in 
various cardiac diseases. 
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p ositron emission tomography (PET) technol- ogy has matured over recent years to be- 
come an established imaging modality for 
the noninvasive characterization of cardiac dis- 
ease. Significant advances in scintigraphic data 
acquisition with multi-slice PET instrumentation 
allow three-dimensional determination of regional 
tissue tracer concentration. Furthermore, an abun- 
dance of radiopharmaceuticals labeled with car- 
bon- l l  (nC), nitrogen-13 (13N), oxygen-15 (150), or 
fluorine-18 (~SF) provide sophisticated delineation 
of specific tissue functions. The temporal definition 
of tissue tracer kinetics and subsequent analysis 
with mathematical models enable quantitative mea- 
surements of physiologic processes such as blood 
flow and metabolic rates. 
Although coronary angiography is considered to 
be the "gold standard" for the characterization of 
coronary artery disease (CAD), data increasingly 
support the importance of noninvasively assessing 
the functional definition of the severity and extent 
of the disease process) Regional measurements 
such as absolute or relative coronary reserve have 
been shown to provide a sensitive marker for the 
functional significance of coronary artery stenoses. 
Such measurements represent functional corre- 
lates to the anatomic definition of vascular abnor- 
malities occurring in CAD. Although these mea- 
surements can be obtained invasively by several 
methods, at the present time PET represents the 
only noninvasive approach that accurately quanti- 
fies regional myocardial perfusion. 2'3 
This review addresses the clinical role of blood 
flow imaging with PET for the detection of CAD, 
using qualitative evaluation of regional tracer distri- 
bution. Additionally, current methods of quantifi- 
cation of regional myocardial blood flow under 
various physiologic conditions are compared. 
RADIOPHARMACEUTICALS 
Several blood flow tracers are available for the 
evaluation of myocardial perfusion using PET 
(Table I). Based on the mode of production, these 
radiopharmaceuticals are divided into two groups. 
Rubidium-82 ([SZRb]-) and copper-62 ([62Cu]-) pyru- 
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TABLE I Extraction Fraction (EF), Tissue and Physical Half-life, 
and Emitted Positron Energy for Tracers Used for Determination 
of Myocardial Blood Flow with PET 
PET Myocardial Blood Flow Tracer 
Tissue Physical Positron 
EF Half-life Half-l i fe Energy MeV 
Generator-produced 
Rubidium-82 ~65% Long(hrs) 1.3 min 3.3 
Copper-62 ~60% Long(hrs) 9.8 rain 2.9 
Cyclotron-produced 
[13N]NH3 ~ 90% Long (hrs) 10 rain 1.2 
PSO]H20 ~ 100% Short (sec) 2 min 1.72 
ttC microspheres ~ 100% Long (hrs) 20 rain 0.96 
valdehyde-bis-(N-4-methylthiosemicarbazone ) 
(PTSM) are generator-produced radiopharmaceu- 
ticals; [13N]NH3, [150]H20, and ~C-labeled com- 
pounds require an on-site cyclotron for their pro- 
duction. 
Generator.produced flow tracers: The stron- 
tium-82 (SZSr)fl2Rb generator-produced flow tracer 
is commercially available. The radiopharmaceuti- 
cal 8ZRb, recently approved by the U.S. Food and 
Drug Administration for the evaluation of myocar- 
dial blood flow, 4 is currently the most practical 
tracer available for PET imaging. The 8ZSr/82Rb 
generator is being used in combination with a 
dedicated infusion system, which permits safe and 
reproducible administration of 82Rb with minimal 
radiation exposure to the technical staff (Figure 1). 
The short physical half-life of 8ZRb (76 seconds) 
allows blood flow measurements in short time 
intervals. By combining the use of 82Rb with phar- 
macologic stress testing, regional myocardial flow 
reserve can be evaluated in about 1 hour, which 
compares very favorably with the time required for 
the acquisition of thallium-201 (/°ITI) or technetium- 
99m (99mTC) isonitrile single-photon emission com- 
puted tomography (SPECT) stress studies. 
The practical advantages of 82Rb are somewhat 
offset by the physiologic and physical properties of 
this tracer. The myocardial extraction fraction of 
82Rb is lower than that of 2°IT1, and it decreases 
considerably with increasing blood flow. There- 
fore, high flow rates produce inaccurate measure- 
ments due to the nonlinear relationship between 
82Rb tissue retention and blood flow. Furthermore, 
82Rb emits positrons with an energy of 3.3 MeV 
that travel a longer distance than those of 13N or I IC 
in tissue before they annihilate with electrons. 
Thus, the image resolution obtainable with 82Rb is 
less than that available with [~3N]NH3 (Table I). 
However, the loss of resolution by the high energy 
of 82Rb positrons is small in comparison to the 
effect of cardiac motion on the spatial resolution of 
nongated cardiac images. 
FIGURE 1. SaSr/eaRb generator mounted to a computer con- 
trolled Infusion system to allow convenient administration 
of the compound to the pat ien t .  
[62Cu]PTSM represents a newly introduced flow 
tracer produced with the zinc-62 (62Zn)/62Cu gener- 
ator. Although this radiotracer has been validated 
only in experimental studies, the preliminary re- 
suits are promising. 5 62Cu has a physical half-life of 
9.8 minutes and, like S2Rb, exhibits a high positron 
energy (Table I). The myocardial extraction of 
PTSM is similar to that of 82Rb, and the clearance 
from myocardial tissue is slow--both desirable 
characteristics for blood flow imaging. The usable 
time period for a 62Zn/6ZCu generator is only about 
24 hours, in contrast to the 82Sr/S2Rb generator, 
which has a shelf life of about 6 weeks. This may 
limit its distribution, as well as the availability of a 
continuous supply of compounds for the evaluation 
of myocardial blood flow. However, in combination 
with a centrally located cyclotron, generator- 
produced flow tracers such as [82Rb]- or [62Cu]PTSM 
can be combined with [~8F]deoxyglucose for the 
simultaneous evaluation of blood flow and tissue 
metabolism without the need of an on-site cyclo- 
tron. 
Cyclotron.produced flow tracers: The cyclo- 
tron-produced tracers most commonly used for the 
evaluation of myocardial blood flow are [13N]NH3 
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and [~50]H20. Figure 2 shows the time course of 
both tracers in myocardial tissue and blood pool, 
following an intravenous bolus injection. The com- 
pound [13N]NH3 has a physical half-life of 10 min, is 
avidly taken up by the myocardium, and clears 
rapidly from the blood pool. It enters the extravas- 
cular space and is converted in myocardial tissue to 
[~3N]glutamine.6 The clearance half-time of 13N 
from the myocardium is slow, and yields a high 
contrast between myocardial and blood activity. 
The retention of 13N in myocardium represents a 
combination of delivery (blood flow) and metabolic 
incorporation. These physiologic and physical prop- 
erties of []3N]NH3 provide excellent image quality 
in combination with PET. 
In patients with severely impaired left ventricu- 
lar function or a history of heavy smoking a 
considerable amount of [13N]NH3 is retained in 
lung tissue, thus decreasing the heart-to-lung activ- 
ity ratio. In contrast to 82Rb, [13N]NH3 is avidly 
taken up by the liver and may, therefore, affect the 
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FIGURE 2. Compadson of myocardial and blood pool time- 
activity curves obtained using ['"OIH20 (above) and 
[~H]NH a (below). 1the arterial Input curve (squares) repre- 
sents Mood pool activity and is similar for both tracers. 
The tissue curve (circles) for ['*N]NH~ demonstrates reten- 
tion of the tracer, yielding high contrast between myocar- 
dial and blood activity as early as I mln after Injection. In 
contrast, the [~O]H,O tissue activity curve shows little 
contrast to blood activity due to rapM back dlfhmion of 
the tracer fTOm tissue. 
evaluation of the inferior wall of the left ventricle if 
the liver is in close proximity to cardiac tissue. 
The compound [150]H20 represents a metaboli- 
cally inert flow tracer. It diffuses freely across 
membranes and is highly extracted by myocardial 
tissue. Animal studies have shown a stable single 
first-pass extraction of [150]H20 over a wide flow 
range, indicating ideal physiologic characteristics 
of this tracer. 22 However, [I~O]H:O retained in 
myocardium diffuses rapidly back into the vascular 
space. Thus, the contrast between ~50 activity in 
the vascular space and myocardial tissue is small. 
In fact, the concentration ratio of blood to tissue 
reaches unity within 60-90 seconds after injection, 
depending on blood flow (Figure 2). Most studies 
employing []50]H20 for the evaluation of myocar- 
dial perfusion are using a separate imaging proce- 
dure with [:SO]carbon monoxide, which labels red 
blood cells, and thus allows for the delineation of 
the vascular space within the myocardium and the 
ventricular chambers. By combining both ap- 
proaches, the vascular activity can be subtracted 
and regional myocardial [~50]H20 retention visual- 
ized. This dual tracer approach may limit the 
clinical application of [150]H20 studies because 
blood pool scans are required under both resting 
and stress conditions. 
Besides [~50]H20 and [13N]NH3, liE or gallium- 
labeled (68Ga) microspheres have been used for the 
assessment of myocardial perfusion. This tracer 
approach is limited to the injection of the tracer 
either into the left atrium or left ventricle, which is 
only possible in the catheterization laboratory. 
QUALITATIVE EVALUATION OF MYOCARDIAL 
PERFUSION 
Qualitative evaluation of regional tracer distri- 
bution using 82Rb and 13N has been employed to 
detect CAD. Taking advantage of the attenuation 
correction provided by PET, relative tracer concen- 
tration is more homogeneous throughout cross- 
sectional images of normal myocardium, as com- 
pared to 2°iT1 SPECT imaging (Figure 3). Recently 
published normal data for regional 2°lTI retention 
on SPECT images demonstrate considerable varia- 
tion between the anterior and inferior walls of the 
left ventricle in a male population, thus indicating 
the significant effect of photon attenuation: Atten- 
uation artifacts are common with 2°~TI SPECT 
imaging and may limit the specificity of this test for 
the diagnosis of CAD. 
PET evaluation of myocardial perfusion at rest 
and during stress provides detection of regional 
perfusion abnormalities with high diagnostic accu- 
racy (Figure 4). Most stress flow studies are per- 
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FIGURE 3. Comparison of normal distribu- 
tion of URb and =°~11 on a polar map display 
representing regional relative tracer con- 
centratlon expressed as percent of maxl. 
mal activity. Data represent average of 15 
"Rb studies (8 male, 7 female) following 
intravenous dlpyrklamole Infusion, Note 
the decreased relat ive =°~11 acUvlty In the 
Inferolateral wall representing soft tissue 
attenuation, lhalllum.2Oldata adapted 
from the Journal o f  Nuclear Medicine. 7 
formed following pharmacologic coronary vasodila- 
tation (dipyridamole, adenosine) because the 
combination of PET with exercise poses technical 
difficulties, especially if the short-lived tracer 82Rb 
is employed. Table II depicts recently published 
diagnostic results using [13N]NH3 or 82Rb in combi- 
nation with PET. Schelbert et al 8 demonstrated 
that use of [~3N]NH3 provides sensitive detection of 
CAD. Gould et al. 9 employed 82Rb in combination 
with dipyridamole in a larger group of patients with 
suspected CAD, and reported a high sensitivity 
and specificity for the detection of disease. Demer 
et al. 1° extended this study to 193 patients. The 
noninvasive assessment of relative coronary re- 
serve by 82Rb PET correlated closely with the 
angiographic definition of the severity of CAD 
employing quantitative measurements. These re- 
sults suggest an excellent diagnostic performance 
of PET flow imaging for the detection of CAD. 
Only a few studies directly compared PET flow 
imaging with 2°1T1 SPECT in the same patient 
population. Tamaki et al. ~1 employed [13N]NH3 
PET imaging together with 2°iT1 SPECT in patients 
with angiographically proven CAD. Both imaging 
procedures yielded a high sensitivity for the re- 
gional detection of disease. However, this study did 
not include a normal control population; thus, no 
conclusions can be drawn about the specificity of 
both imaging modalities. 
More recently, two investigations compared S2Rb 
PET imaging with 2°1T1 SPECT imaging in the same 
patient population. In the first study of 132 pa- 
tients, Go et a112 from the Cleveland Clinic re- 
ported a significantly higher diagnostic accuracy of 
82Rb PET imaging for the detection of CAD. 
Sensitivity and specificity of 82Rb PET were higher 
than those of 2°lT1 SPECT and yielded a signifi- 




Coronary Artery Disease 
(2149128) 
FIGURE 4. Cross-sectional "Rb images of 
patient with significant left anterior de- 
scending artery (LAD) stenosl~ The resting 
studx_ below shows homogenous myocar. 
dial =Rb activity. Following Inlbravenous 
dlpyridamole infusion, a marked perfuslon 
abnormality Is noted in the anteroseptal 
wall consistent with Impaired coronary re- 
serve In the LAD territory. Note the dilata- 
tion of left vent=lcular chamber as indirect 
evidence of the significance of the dipy- 
ridamole-lnduced perfmdoa abnormality. 
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TABLE I I  Diagnostic Performance of PEi" and TI-201 SPECT for Detection of Coronary Artery Disease  
PET SPECT 
First 
Author N Tracer Stress Sen (%) Spee (%) Acc (%) N Sen (%) Spec (%) Aec (%) 
Schelbert et al" (1982) 32 NH 3 Dip 97 100 98 . . . .  
Demer et all° (1989) 193 NHzRb Dip 94 95 94 . . . .  
Stewart et al ~3 (1991) 81 Rb Dip 85 89 86 81 83 61 77 
Go et al ~z (1990) 132 Rb Dip 95 82 92 135 79 76 78 
Tamaki et al u (1985) 48 NH3 Ex 98 - -  - -  48 96 - -  - -  
N = Number of patients: 492 94 92 93 264 86 69 78 
Acc = accuracy; Dip = dipyridamole; Ex = bicycle ergometer; NH 3 = [13N]arnmonia; Rb = Rubidium-82; Sen = sensitivity; Spec = specificity. 
PET as compared with 76% for SPECT. Both 
imaging procedures followed a single infusion of 
dipyridamole, thus avoiding the variability of re- 
peated stress testing in the study population. The 
results of the second study, performed at the 
University of Michigan, failed to confirm the higher 
sensitivity of 82Rb PET for detection of CAD. 1~ 
Both PET and SPECT identified disease correctly 
in about 85% of the cases. However, PET signifi- 
cantly out-performed SPECT in terms of specificity 
(Table II). The overall diagnostic accuracy of PET 
and SPECT agreed closely with the data obtained 
by Go et alJ 2 Although patient selection for cardiac 
catheterization may explain the low specificity of 
2°~TI SPECT described by the Michigan study, 
several recent studies indicate the relatively high 
incidence of false-positive 2°~TI SPECT resultsJ 4'15 
82Rb PET showed a significantly lower rate of 
false-positive findings in the same patient popula- 
tion. The diagnostic difference was most obvious in 
the diagnosis of disease involving the inferior wall 
of the left ventricle. Diaphragmatic attenuation 
artifacts appear to be less common with 82Rb PET 
imaging, which clearly indicates the limitations of 
the low energy tracer 2°1T1 for SPECT imaging. 
Future use of 99mTc-labeled radiopharmaceuticals 
may overcome some of these limitations, but sophis- 
ticated attenuation correction of SPECT images 
may be required to match the advanced imaging 
technology provided by PET instrumentation. 
Thus, PET in combination with 82Rb or []3N]NH3 
yields higher diagnostic accuracy for detection of 
CAD as compared to 2°tTl SPECT. This primarily 
reflects the improvement of scintigraphic data 
acquisition provided by PET. Preliminary studies 
analyzing the cost of PET imaging and its impact 
on the management of patients with proven or 
suspected CAD suggest an overall cost-saving ef- 
fect due to less unnecessary cardiac catheteriza- 
tion.~6 However, the question remains whether the 
higher diagnostic accuracy of this modality justifies 
the increased costs involved with this test. Further 
investigation will define the economic cost-benefit 
ratio of PET flow imaging for detection of CAD. 
QUANTIFICATION OF MYOCARDIAL BLOOD 
FLOW BY PET 
As outlined above, PET provides the most 
sophisticated technology to quantify regional tracer 
concentration in the myocardium. The time course 
of tracer distribution in myocardium and blood can 
be defined by using dynamic image acquisition. 
The most commonly used flow tracers are [13N]NH3 
and [150]H20. In order to quantify myocardial 
blood flow in units of ml/min/100 g, the accumula- 
tion and fate of the radiopharmaceutical in myocar- 
dial tissue must be described by appropriate math- 
ematical models. The exchange of tracer between 
vascular space and tissue is commonly described in 
terms of compartmental models. These models rely 
on two basic assumptions: first, the tracer is homo- 
geneously distributed in these compartments; and 
second, the transfer from compartments occurs 
with conservation of mass. Theory and application 
of compartmental analysis require the develop- 
ment of a current model for the behavior of any 
particular tracer in the biologic system. Knowledge 
about the physiologic behavior of the tracer should 
provide justification for the specific structure as 
well as the parameters of the compartmental model. 
The configurations of compartmental models 
used frequently for quantification of blood flow are 
shown in Figure 5. The two-compartmental model 
consists of a vascular as well as an extravascular 
compartment. It is most applicable to the descrip- 
tion of the tracer kinetics of freely diffusable blood 
flow tracers such as [150]H20. The injected tracer 
is delivered by the vascular space, diffuses immedi- 
ately across the membrane, and equilibrates within 
the tissue. The exchange between the two compart- 
ments is expressed by the rate constants Ks and k 2. 
In case of freely diffusable tracers, values for blood 
flow are usually derived from the estimation of ks, 
which represents the clearance of activity from 
tissueJ 7 
In contrast, the description of tissue kinetics for 
[13N]NH3 requires a more complex three-compart- 
mental model (Figure 5). The vascular compart- 
ment represents the tracer concentration in plasma 
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FIGURE 5. Tracer kinetic models employed for determina- 
tion of blood flow using PET data. 1he model used for 
[~O]H20 (above) Is based on the principle of inert gas ex- 
change and con be described by a single tissue, 2-com- 
partmental model, x7 The flow (F) is computed from the 
washout rate constant k 2 according to the formula k 2 = 
F/p, where p represents the partition coefficient of water 
between Mood and tissue. The myocardial retention of 
[UN]NH: depends on its metabolic Incorporation Into glu- 
tamlne via the  glutamate-glutamlne pathway. A 3-com- 
partmeutal model Including the rate constants Kx, k2, and 
ks has to he used to separate initial extraction from back- 
diffusion (k:) and retention (k:). K: is usually written with a 
capital letter in order to indicate that  it expresses a clear- 
ance rate constant rather then a transfer rate constant. 
The plasma activity concentration has the dimension 
~Lmol/ml and the activity concentration In t issue the  dl- 
menslen i*mol/g, where K x Is expressed In ml/mln/100 g as 
an index of myocardial blood flow. The rate constants k2-k 4 
are expressed in mln "~. 
of the coronary capillaries. The two extravascular 
compartments represent different chemical states 
of the tracer but do not distinguish between anatom- 
ically separable spaces. Within the extravascular 
compartment, the tracer competes for back diffu- 
sion into the vascular space (k2) and transfer into 
the metabolic compartment (k3). In the case of 
[UN]NH3, the label is trapped in the myocardium in 
the form of [UN]glutamine.~8 The release of 13N 
activity from myocardium is very slow. Therefore, 
for the description of [BN]NH3 kinetics, k4 (describ- 
ing the metabolism of [UN]glutamine) can be 
neglected in view of the short physical half-life of 
[13N]NH3 (10 minutes). In this model, the blood 
flow equals K~ times the single-pass extraction 
fraction of the tracer. [13N]NH3 is extracted from 
blood with a high extraction fractional Based on 
experimental data by Schelbert et al. ~8 the single- 
pass extraction fraction only slightly decreases in 
high-flow states, and is assumed to be greater than 
90%, even for flow values up to 500 ml/min/100 g of 
tissue. However, the net retention of [BN]NH3 in 
• . / 
myocardial tissue depends on flow and the  meta- 
bolic incorporation of [13N]NH3. Because not all of 
the activity entering the extravascular compart- 
ment is metabolized, the assessment of flow based 
on retained [13N]NH3 activity underestimates myo- 
cardial blood flow. This is most apparent during 
high-flow states where k 3 becomes the rate-limiting 
step for the incorporation of the label into the 
metabolic compartment. Thus, to minimize under- 
estimation of high flow states, a tracer kinetic 
model separating K] and k3 is necessary. Detailed 
descriptions of the tracer kinetic models employed 
for [~50]H20 and [13N]NH3 are provided by 
Hutchins et al, 3 Iida et al, 19 Krivokapich et al, 2° and 
Bergmann et al. 2 
COMPARISON OF [UN]NH3 AND [~O]H20 
QUANTITATIVE FLOW MEASUREMENTS: 
Both [13N]NH3 and [150]H20 have inherent 
physiologic and physical advantages and disadvan- 
tages as imaging agents. [13N]NH3 kinetics in myo- 
cardium are more complex than those of [~50]H20, 
but the longer physical half-life of [t3N]NH3 and 
retention in myocardial tissue make it a superior 
imaging agent. On the other hand, [t50]H20 exhib- 
its almost ideal physiologic properties as a flow 
tracer. However, its short physical half-life and 
high activity in the vascular space are challenging 
for current imaging instrumentation. As a result, 
different kinetic models must be used for quantifi- 
cation of blood flow based on [13N]NH3 or []50]H20 
kinetics. 
As discussed above, the difference between 
both tracer kinetic models can be expressed by 
specific rate constants that describe myocardial 
blood flow. In the case of [UN]NH3, the rate 
constant K] is used, while the washout rate con- 
stant k 2 describes blood flow in the [~50]H20 
model. At different physiologic and pathophysio- 
logic states, K~-based flow measurements are sensi- 
tive to changes of the extraction fraction. 2~ Esti- 
mates of myocardial blood flow by the [~50]H20 
method reflect k2 and the partition coefficient of 
water among plasma, red blood cells, and myocar- 
dial tissue, which may also vary under different 
pathophysiologic conditions. = In contrast to the 
metabolically inert [~50]H20, []3N]NH3 is rapidly 
metabolized in the liver following intravenous injec- 
tion, and ]3N-labeled metabolites appear rapidly in 
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blood. 6 The quantification of regional myocardial 
blood flow by [13N]NH3 requires the definition of 
the arterial input function. Recent studies indicate 
that the effect of t3N metabolites in blood on 
myocardial blood flow measurements is relatively 
small, and correction for metabolic contamination 
may not be necessary. 3 
The major advantage of [150]H20 is that blood 
flow measurements are less affected by partial 
volume effect. The spatial resolution provided by 
current PET instrumentation ranges between 6 
and 10 mm. In the human heart, the left ventricular 
wall thickness averages between 10 to 20 mm, 
depending on the degree of wall thickening during 
the cardiac cycle. Thus, the recovery of tracer 
information from the left ventricular wall is ini]u- 
enced by partial volume effect. Undersampllng 
becomes most prominent if the left ventricular wall 
is thinned, such as in patients with previous myocar- 
dial infarction or severe contractile dysfunction. 23 
Because flow measurements with [~50]H20 are 
based on the washout of activity (relative change of 
activity), the partial volume effect is less important 
for the accurate estimate of clearance kinetics. 
Conversely, [13N]NH3 flow measurements depend 
on the accurate estimate of the initial uptake of 
this tracer in the myocardium. These measure- 
ments are sensitive to the partial volume effect. 24'25 
Thus, in areas of previous myocardial infarction, it 
is expected that [13N]NH3 blood flow measure- 
ments will underestimate the true myocardial blood 
flow. 
Although clearance kinetics are less sensitive to 
partial volume effects, Monte-Carlo simulations 
have shown that the coefficient of variation for a 
washout rate constant is about 3 times higher than 
the same coefficient for an uptake rate constant. It 
is obvious that further research is required to 
define the relative error sensitivity of uptake pa- 
rameters ([J3N]NH3) and washout parameters 
([~50]H20) under various physiologic and patho- 
physiologic conditions. 
It is expected that myocardial blood flow can 
also be quantified using [S2Rb]- and [62Cu]PTSM. 
Current research is focusing on the development of 
a kinetic model for 82Rb. The kinetics of 82Rb 
resemble those of 2°~TI. However, the short half-life 
of this tracer requires PET instrumentation with 
high sensitivity and count-rate capabilities for the 
accurate definition of time-activity curves. 
APPUCATION OF qUANTITATIVE FLOW 
MEASUREMENTS BY PET 
Shah et a126 compared the retention of [13N]NH3 
in canine myocardium with blood flow as assessed 
by radiolabeled microspheres. As expected, a non- 
linear relationship between both measurements 
was observed. This accompanied a significant under- 
estimation of myocardial blood flow based on the 
retained [13N]NH3 activity at high-flo~ states (Ta- 
ble III). With the introduction of a tracer kinetic 
model that corrects for the decreas!ng retention 
fraction at high flows, a linear relatiottship between 
[13N]NH3 and microspheres blood flow could be 
demonsti'ated over a wide flow range. 27 
Bergmann et al. 2 validated [150]H20 flow mea- 
surements in the canine model. Again, comparing 
scintigraphic measurements with microspheres 
blood flow, these investigators demonstrated a 
linear relationship between both measurements 
over a flow range from 30 to 500 ml/min/l(J0 g 
(Table III). The correlation coefficient for both 
measurements was 0.95, which indicates the accu- 
racy of these measurements in the animal model. 
Quantitative measurements of regional myocar- 
dial blood flow in human myocardium have been 
performed with both [t3N]NH3 and [~50]HzO. Blood 
flow measurements at rest and following pharmaco- 
logic stress are in close agreement with data 
previously obtained by coronary sinus catheteriza- 
tion or Doppler flow catheters (Table IV). The 
relative increase of myocardial blood flow (coro- 
nary reserve) in normal volunteers was greater 
than 4 to 1, which again agrees closely with indepen- 
dent measures of coronary reserve by Doppler 
catheters and studies performed in the animal 
model. 1 Quantitative flow measurements during 
stress (Table IV) indicate that the increase in 
myocardial blood flow is greater following dipyrida- 
mole infusion than following exercise. This may 
reflect the difficulty of reaching adequate cardiac 
workload with bicycle exercise during PET imag- 
ing. 2° 
The noninvasive determination of coronary re- 
serve by pharmacologic means may provide a 
useful and reproducible parameter for the func- 
I'.4UlUE I I I  Correlation of PET and Microspheres Flow Measurements in Canine Myocardium 
Flow Range 
Author Tracer [ml/min/lO0 g] Correlation 
Bellina et aF 7 (1990) L3NH3 20-500  y = - 0 .18  + 1.08x (R = 0.96) 
Bergmann et al ~ (1989) H2~SO 29-504  y = 0.00 + 1.06x (R = 0.95) 
Shah et a126 (1985) 13NH3 44-200  y = -36 .2  + 1.53x - O.13(J27x 2 (R = 0.94) 
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TABLE IV Myocardial Blood Flow in Humans Determined by PET with PaN]Ammonia or [1sO]Water 
Rest Flow Stress Flow" 
Author Tracer [ml/min/lO0 g] [ml/min/lO0 g] Stress/Rest Stress 
Araujo et al 2° (1990) H21S0 88 ± 8 352 -- 112 4.00 Dipyridamole 
93 +- 21" 132 ± 27* 1.42" 
Bergmann et al 2 (1989) H2150 90 -+ 22 355 ± 115 3.94 ~ Dipyridamole 
Hutchins et aP (1990) I~NH3 88 ± 17 417 - 112 4.74 Dipyridamole 
Krivokapich et al a3 (1989) ~3NH3 70 ± 17 135 ± 22 1.93 Bicycle ergometer 
*Post-stenotic vascular territories. 
tional assessment of severity of CAD. Results by 
Araujo et a128 and Walsh et a129 indicate that the 
regional coronary reserve is markedly decreased in 
poststenotic ventricular segments. Walsh et al '9 
studied patients undergoing coronary angioplasty 
prior to and following this procedure. The coro- 
nary reserve averaged 1.3 in the stenotic area prior 
to angioplasty but increased to 3.3, 5 days after 
revascularization. Thus, quantitative flow measure- 
ments may be used following angioplasty for the 
objective assesment of the intervention results, and 
also as a predictive parameter for restenosis. 
In addition to useful diagnostic and prognostic 
information in patients with CAD, quantitative 
flow measurements can also provide an objective 
assessment of drug therapy. Such measurements 
can also be applied in cardiac diseases character- 
ized by global changes in blood flow. 
Flow measurements based on relative tracer 
distribution are of limited use in such disease 
groups. In patients with chest pain and normal 
coronary arteries, [tsO]H20 blood flow measure- 
ments have been shown to identify decreased 
coronary reserve. 3° Thus, among angina patients, 
PET may provide a unique diagnostic means to 
identify those patients with presumably small- 
vessel CAD. 
Quantitative flow measurements have also been 
employed in patients with cardiac transplants. 3t 
Few studies have suggested that the coronary 
reserve is reduced in patients with transplant 
rejection. This indicates altered coronary hemody- 
namics, with further studies required to define the 
diagnostic yield of such measurements in the fol- 
low-up of patients with cardiac transplantation. 
Although the coronary reserve represents a 
sophisticated tool to describe the functional state 
of the coronary vasculature, its magnitude is af- 
fected by physiologic processes. For example, ele- 
vated blood pressure and heart rate increase rest- 
ing blood flow and decrease coronary reserve. 32 On 
the other hand, pharmacologic action of dipyrida- 
mole or adenosine may be attenuated in some 
patients, especially if they take medications known 
to interact with these drugs. Therefore, the inter- 
pretation of flow measurements in patients with 
various cardiac diseases requires careful consider- 
ation of all factors which may affect the magnitude 
of global and regional coronary reserve. 
CONCLUSION 
PET provides an advanced imaging technology 
that allows the accurate definition of regional 
tracer distribution. This technology, in combina- 
tion with 82Rb and [t3N]NH3, allows for the sensi- 
tive and specific detection of CAD. Several studies 
indicate the superiority of this approach in compar- 
ison to standard 2°ITI SPECT imaging. However, 
further studies are needed to define the cost- 
benefit ratio of this technology for the management 
of patients with suspected or proven CAD. 
PET represents the most accurate noninvasive 
means to measure regional blood flow and can be 
used in combination with pharmacologic stress 
tests to quantify regional coronary reserve. Tracer 
kinetic models for [UN]NH3 and [tSO]H20 provide 
accurate flow estimates over a wide flow range. 
Quantitative flow measurements by PET provide a 
sophisticated tool for research and clinical charac- 
terization of patients with CAD. Short-lived radio- 
pharmaceuticals used for PET allow the combined 
evaluation of flow and other tissue functions such 
as metabolism, which may prove useful in the 
assessment of the extent and severity of myocardial 
disease. 
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